A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

Key facts

Sponsor

Cue Biopharma

Principal Investigator

Matteo Levisetti, MD

Cue Biopharma

Intervention

CUE-101(drug)

Enrollment

80 target

Eligibility

18 years · All sexes

Timeline

2019 – 2026

Study locations (17)

• University of Arizona, Tucson, Arizona, United States
• Stanford University Medical Center, Palo Alto, California, United States
• Yale School of Medicine, New Haven, Connecticut, United States
• George Washington University Cancer Center, Washington D.C., District of Columbia, United States
• Moffitt Cancer Center, Tampa, Florida, United States
• Emory University School of Medicine, Atlanta, Georgia, United States
• Affiliated Oncologists, LLC, Chicago, Illinois, United States
• Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
• Massachusetts General Hospital, Boston, Massachusetts, United States
• University of Michigan, Ann Arbor, Michigan, United States
• Barbara Karmanos Cancer Center/ Wayne State University School of Medicine, Detroit, Michigan, United States
• Washington University, St Louis, Missouri, United States
• Memorial Sloan Kettering Cancer Center, New York, New York, United States
• Gabrail Cancer Center, Canton, Ohio, United States
• Vanderbilt-Ingram Cancer Center (VICC), Nashville, Tennessee, United States
• +2 more locations on ClinicalTrials.gov

Collaborators

Merck Sharp & Dohme LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Squamous cell carcinoma of the oropharynx

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06915038
  ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx
  Indiana University
• RECRUITINGPHASE1NCT06747390
  Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery
  Ryan Carey
• RECRUITINGPHASE2NCT06702033
  The Minimalist Trial-2
  Washington University School of Medicine
• RECRUITINGPHASE1NCT06589609
  Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer
  BlueSky Immunotherapies GmbH
• RECRUITINGPHASE2NCT06223568
  Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
  National Cancer Institute (NCI)
• RECRUITINGPHASE2NCT05582122
  SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers
  UNICANCER
• ACTIVE NOT RECRUITINGNCT06592716
  Can Recurrence of Cancer in the Oropharynx be Detected by Blood Samples?
  Rigshospitalet, Denmark
• RECRUITINGPHASE2NCT06323460
  Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
  Ohio State University Comprehensive Cancer Center

See all trials for Squamous cell carcinoma of the oropharynx →